Cancer Center Clínica Universidad de Navarra (CCUN)
Centro clínico de la Universidad de Navarra
Javier
Cortés Castán
Publications by the researcher in collaboration with Javier Cortés Castán (48)
2023
2022
2021
-
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
npj Breast Cancer, Vol. 7, Núm. 1
-
The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers
npj Breast Cancer, Vol. 7, Núm. 1
2020
-
A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428
-
Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals
Frontiers in Oncology, Vol. 10
-
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
The Lancet Oncology, Vol. 21, Núm. 4, pp. 519-530
2019
2018
-
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
EMBO Molecular Medicine, Vol. 10, Núm. 12
-
P95HER2–T cell bispecific antibody for breast cancer treatment
Science Translational Medicine, Vol. 10, Núm. 461
-
Perspectives on preoperative systemic treatment and breast conservative surgery: One step forward or two steps back?
Breast, Vol. 41, pp. 133-135
-
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
Annals of Oncology, Vol. 29, Núm. 5, pp. 1203-1210
2017
-
18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial
Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441
-
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624
-
Critically short telomeres and toxicity of chemotherapy in early breast cancer
Oncotarget, Vol. 8, Núm. 13, pp. 21472-21482
-
Role of total tumour load of sentinel lymph node on survival in early breast cancer patients
Breast, Vol. 33, pp. 8-13
2016
-
Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response
Annals of Surgical Oncology, Vol. 23, Núm. 12, pp. 3831-3837
-
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
Annals of Oncology, Vol. 27, Núm. 11, pp. 2046-2052
-
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer
Oncotarget, Vol. 7, Núm. 35, pp. 56295-56308
-
Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts
Oncotarget, Vol. 7, Núm. 42, pp. 67956-67965